Diagnostic value of CD56 immunohistochemistry in thyroid lesions

Pyo, Jung‐Soo; Kim, Dong-Hoon; Yang, Jeongmo

doi:10.1177/1724600817748538

Cited by 20 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoplasms of neuroendocrine or hematopoietic origins over‐produce NCAM, as do brain tumours (Jensen & Berthold, 2007; Zecchini & Cavallaro, 2010). Conversely, in pancreatic (Fogar et al, 1997), colorectal (Roesler, Srivatsan, Moatamed, Peters, & Livingston, 1997) astrocytic (Sasaki et al, 1998) and thyroid (Muthusamy et al, 2018; Pyo, Kim, & Yang, 2018) cancer, low levels of NCAM have been correlated with increased malignancy. In prostate cancer, however, the role of NCAM has not been investigated.…”

Section: Discussionmentioning

confidence: 99%

miR‐210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells

Angel

Lynch

Nesbitt

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Hypoxia in prostate tumours has been associated with disease progression and metastasis. MicroRNAs are short noncoding RNA molecules that are important in several cell processes, but their role in hypoxic signalling is still poorly understood.miR-210 has been linked with hypoxic mechanisms, but this relationship has been poorly characterised in prostate cancer. In this report, the link between hypoxia and miR-210 in prostate cancer cells is investigated. Polymerase chain reaction analysis demonstrates that miR-210 is induced by hypoxia in prostate cancer cells using in vitro cell models and an in vivo prostate tumour xenograft model. Analysis of The Cancer Genome Atlas prostate biopsy datasets shows that miR-210 is significantly correlated with Gleason grade and other clinical markers of prostate cancer progression. Neural cell adhesion molecule (NCAM) is identified as a target of miR-210, providing a biological mechanism whereby hypoxia-induced miR-210 expression can contribute to prostate cancer. This study provides evidence that miR-210 is an important regulator of cell response to hypoxic stress and proposes that its regulation of NCAM may play an important role in the pathogenesis of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‐210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells

Angel

Lynch

Nesbitt

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…For instance, Hector Battifora Mesothelial Cell-1 (HBME-1), Galectin-3 and Cytokeratin-19 (CK19) have been the most frequently used antibodies in thyroid pathology, although a wide range of sensibility and specificity values of these markers has been reported 3,6,[11][12][13][14][15] . The rates of loss of CD56 IHC expression were significantly higher in malignant thyroid tumors, such as papillary thyroid carcinoma and follicular carcinoma than in FA and other benign lesions, such as follicular adenoma, benign follicular nodule, and Hashimoto's thyroiditis 16 .…”

Section: Introductionmentioning

confidence: 86%

Application of Galectin-3, HBME-1, Cytokeratin-19, and CD56 in the Diagnosis of Thyroid Neoplasm

Okdoo,

Lkhagvadorj,

Malchinkhuu

et al. 2019

Cent. Asian j. Med. Sci.

View full text Add to dashboard Cite

The purpose of this study was to investigate the effectiveness of immunohistochemical thyroid malignancy markers Galectin-3, HBME-1, Cytokeratin-19, and CD56 in the diagnosis of thyroid neoplasm. Methods: The study included a total of 53 cases of thyroid neoplasm on which immunohistochemical IHC staining was performed using the manual staining method. Results: The histopathological diagnosis of thyroid nodules was papillary thyroid carcinoma in 40 (75.5%), follicular thyroid carcinoma in 3 (5.7%), follicular adenoma in 8 (15.1%), medullary thyroid carcinoma in 1 (1.9%), and Hurthle cell carcinoma in 1 (1.9%). Out of 40 cases of papillary thyroid carcinoma, Galectin-3 and CK19 were positive in 36 (90%) cases while expression of HBME1 was seen in 32 (80%) papillary thyroid carcinoma cases, and 16 (40%) stained positive for CD56. For the three follicular thyroid carcinoma cases, CD56 was positive in one case, but the marker was positive in 7 out of 8 cases (87.5%) of follicular adenoma. Conclusion: Our results suggest Galectin-3 and HBME-1 are the most sensitive diagnostic markers for differentiating papillary carcinoma from follicular neoplasm.

show abstract

“…CD56 is a neural cell adhesion molecule and is characteristically expressed in normal thyroid follicular cells and benign thyroid nodules but not in PTC [7][8][9][10]. That CD56 works well as a diagnostic marker for PTC against benign thyroid lesions has been shown in several previous studies [11][12][13]. However, little is known about the CD56 expression in NIFTP and the uncommon variants of PTC, such as the tall cell variant.…”

Section: Introductionmentioning

confidence: 99%

“…A few studies have shown that follicular variant PTC (FVPTC) has reduced expression of CD56 expression compared to benign thyroid nodules, suggesting the utility of CD56 immunostaining for the differential diagnosis [14]. Although most authors agree that CD56 expression is reduced in the process of thyroid carcinogenesis [14][15][16][17], there is still a lack of data about the CD56 expression in different variants of PTC other than classic PTC or about the utility of CD56 as a diagnostic marker in rare PTC variants [13].…”

Section: Introductionmentioning

confidence: 99%

CD56 Expression in Papillary Thyroid Carcinoma is Highly Dependent on the Histologic Subtype: A Potential Diagnostic Pitfall

Cho

Kim

Jeon

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Loss of CD56 expression has been regarded as a diagnostic marker of papillary thyroid carcinoma (PTC). However, certain variants of PTC can aberrantly express CD56. Methods Using a digital-image analysis tool, we evaluated H-scores of CD56 immunostaining in 216 thyroid tumors. Results The H-score of the CD56 of all PTCs was lower than that of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (p < 0.001). The H-scores of CD56 were lower in classic PTC, the infiltrative follicular variant, and the diffuse sclerosing variant than in other PTC variants (p < 0.001), whereas the H-scores were higher in tall cell variant, Warthin-like variant, and cribriform-morular variant than in classic PTC (p < 0.001). The optimal cut-off value of H-scores for the CD56 expression was 180 for differentiating the NIFTP from the follicular adenoma and 30 for the differential diagnosis of NIFTP and infiltrative follicular variant PTC. Conclusions CD56 expression is predominantly lost in classic and infiltrative follicular variants of PTCs and more preserved in the other histologic subtypes of PTC and NIFTP. CD56 is particularly useful for differentiating PTC from follicular-pattern thyroid neoplasms, but the aberrant expression in uncommon variants of PTC could be a diagnostic pitfall.

show abstract

Diagnostic value of CD56 immunohistochemistry in thyroid lesions

Cited by 20 publications

References 18 publications

miR‐210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells

miR‐210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells

Application of Galectin-3, HBME-1, Cytokeratin-19, and CD56 in the Diagnosis of Thyroid Neoplasm

CD56 Expression in Papillary Thyroid Carcinoma is Highly Dependent on the Histologic Subtype: A Potential Diagnostic Pitfall

Contact Info

Product

Resources

About